| scholarly article | Q13442814 |
| P50 | author | William J. Jagust | Q56863004 |
| Daniel R Schonhaut | Q57055541 | ||
| Henry D Schwimmer | Q87405441 | ||
| Gil D Rabinovici | Q87489631 | ||
| Rik Ossenkoppele | Q87490049 | ||
| Mustafa Janabi | Q88372236 | ||
| Michael Schöll | Q42334678 | ||
| P2093 | author name string | James P O'Neil | |
| Suzanne L Baker | |||
| Jacob W Vogel | |||
| Samuel N Lockhart | |||
| Jamie Faria | |||
| P2860 | cites work | Regional Distribution of Neurofibrillary Tangles and Senile Plaques in the Cerebral Cortex of Elderly Patients: A Quantitative Evaluation of a One-Year Autopsy Population from a Geriatric Hospital | Q22242921 |
| Neuropathological alterations in Alzheimer disease | Q27003314 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| Trans-synaptic spread of tau pathology in vivo | Q28732288 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease | Q29617286 | ||
| Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers | Q29620245 | ||
| The intersection of amyloid beta and tau at synapses in Alzheimer's disease | Q34054680 | ||
| Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment | Q34198357 | ||
| Neural compensation in older people with brain amyloid-β deposition | Q34253028 | ||
| Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies | Q34327435 | ||
| Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study | Q34332159 | ||
| Primary age-related tauopathy (PART): a common pathology associated with human aging | Q34445021 | ||
| Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. | Q48718975 | ||
| Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. | Q48784648 | ||
| Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. | Q48835886 | ||
| Observations on the brains of non-demented old people | Q49150147 | ||
| Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease | Q77614817 | ||
| PART is part of Alzheimer disease | Q34460027 | ||
| PART, a distinct tauopathy, different from classical sporadic Alzheimer disease | Q34467464 | ||
| Correction for partial volume effects in PET: principle and validation | Q34468480 | ||
| Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration | Q34518577 | ||
| Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry | Q34556945 | ||
| National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease | Q34635272 | ||
| Alzheimer Disease Pathology in Middle Age Reveals a Spatial-Temporal Disconnect Between Amyloid-β and Phosphorylated Tau | Q35004256 | ||
| Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging | Q35204334 | ||
| Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study | Q35219292 | ||
| Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy | Q35241767 | ||
| Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant | Q35592672 | ||
| The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features | Q36217479 | ||
| Relation of neuropathology to cognition in persons without cognitive impairment | Q36374970 | ||
| Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease | Q36408912 | ||
| Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature | Q36575903 | ||
| Distribution volume ratios without blood sampling from graphical analysis of PET data | Q36817029 | ||
| Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue | Q36987267 | ||
| Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium | Q37137198 | ||
| Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects | Q37181281 | ||
| Amyloid deposition, hypometabolism, and longitudinal cognitive decline | Q37207254 | ||
| Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis | Q37336139 | ||
| Neuropathology of older persons without cognitive impairment from two community-based studies | Q38405842 | ||
| Cerebrospinal fluid biomarkers mirror rate of cognitive decline | Q38457762 | ||
| Episodic memory in normal aging and Alzheimer disease: Insights from imaging and behavioral studies | Q38575873 | ||
| Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults | Q40253365 | ||
| Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. | Q40415499 | ||
| Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model | Q41868802 | ||
| Frequency of stages of Alzheimer-related lesions in different age categories | Q42445469 | ||
| [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease | Q42712929 | ||
| Age-associated cognitive decline | Q43536493 | ||
| Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents | Q44474556 | ||
| Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease | Q44657447 | ||
| Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. | Q45810537 | ||
| Pathological tau disrupts ongoing network activity | Q47744611 | ||
| Alzheimer neuropathologic alterations in aged cognitively normal subjects | Q48226793 | ||
| Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 | ||
| Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. | Q48448000 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 971-982 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Neuron | Q3338676 |
| P1476 | title | PET Imaging of Tau Deposition in the Aging Human Brain | |
| P478 | volume | 89 |
| Q46616293 | 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study |
| Q41600997 | 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease |
| Q37739887 | 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. |
| Q37198563 | 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers |
| Q53396939 | 18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. |
| Q39270980 | A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies |
| Q57927766 | A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease |
| Q37590389 | A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease |
| Q39451637 | A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley? |
| Q39434968 | A clinicopathological approach to the diagnosis of dementia |
| Q38714558 | A comparison of five partial volume correction methods for Tau and Amyloid PET imaging with [18F]THK5351 and [11C]PIB. |
| Q90140035 | A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia |
| Q58778649 | A novel partial volume correction method for accurate quantification of [F] flortaucipir in the hippocampus |
| Q99623684 | A probabilistic atlas of locus coeruleus pathways to transentorhinal cortex for connectome imaging in Alzheimer's disease |
| Q42365992 | A protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimer's disease. |
| Q39039980 | A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer's disease. |
| Q64245708 | A walk through tau therapeutic strategies |
| Q26745508 | A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers |
| Q38653494 | AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure |
| Q37633577 | AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies |
| Q90198060 | Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development |
| Q53397162 | Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. |
| Q38812890 | Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study |
| Q91045286 | Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimer's disease |
| Q74439119 | Ageing protein imaged in brain |
| Q37504961 | Aging Affects Dopaminergic Neural Mechanisms of Cognitive Flexibility |
| Q91781242 | Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species |
| Q38893744 | Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology |
| Q53385578 | Alzheimer disease in 2016: Putting AD treatments and biomarkers to the test. |
| Q42656263 | Alzheimer's drug-development pipeline: 2016. |
| Q91744531 | Amide proton transfer-weighted magnetic resonance imaging of human brain aging at 3 Tesla |
| Q88755570 | Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease |
| Q47194750 | Amyloid Associated Intermittent Network Disruptions in Cognitively Intact Older Subjects: Structural Connectivity Matters |
| Q38945395 | Amyloid and tau PET demonstrate region-specific associations in normal older people. |
| Q83225104 | Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity |
| Q92315625 | Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age |
| Q60530541 | Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis |
| Q89751795 | Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity |
| Q47937013 | Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation |
| Q64107058 | Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies |
| Q89855898 | Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease |
| Q57214180 | Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging |
| Q37600680 | Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study |
| Q46158333 | Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals |
| Q45974423 | Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease. |
| Q95278331 | Associations between NIH Toolbox Cognition Battery and in vivo brain amyloid and tau pathology in non-demented older adults |
| Q91615306 | Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum |
| Q91999679 | Associations between self-reported sleep characteristics and incident mild cognitive impairment: The Heinz Nixdorf Recall Cohort Study |
| Q64261095 | Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease |
| Q51766183 | Atypical Localization and Dissociation between Glucose Uptake and Amyloid Deposition in Cognitively Normal APOE*E4 Homozygotic Elders Compared with Patients with Late-Onset Alzheimer's Disease. |
| Q64106160 | Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue |
| Q95278387 | Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease |
| Q92017890 | Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET Applications |
| Q64952063 | Biomarkers for tau pathology. |
| Q38979999 | Biomarkers for the Early Detection and Progression of Alzheimer's Disease |
| Q39413097 | Biomarkers in Neurodegenerative Diseases |
| Q93222023 | Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts |
| Q64967643 | Brain Molecular Connectivity in Neurodegenerative Diseases: Recent Advances and New Perspectives Using Positron Emission Tomography. |
| Q90414751 | Brain Theranostics and Radiotheranostics: Exosomes and Graphenes In Vivo as Novel Brain Theranostics |
| Q64950892 | Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography. |
| Q50533425 | Brain volume change and cognitive trajectories in aging. |
| Q99631054 | CSF glucose tracks regional tau progression based on Alzheimer's disease risk factors |
| Q59807550 | CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume |
| Q47587631 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry |
| Q88574025 | Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects |
| Q53390673 | Cognition and anatomy of adult Niemann-Pick disease type C: Insights for the Alzheimer field. |
| Q51825935 | Cognitive Domain Dispersion Association with Alzheimer's Disease Pathology. |
| Q47658947 | Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease |
| Q38739937 | Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease |
| Q45752126 | Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data |
| Q47285480 | Continuous measurement of object location memory is sensitive to effects of age and mild cognitive impairment and related to medial temporal lobe volume. |
| Q90214060 | Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology |
| Q83228796 | Cortical tau deposition follows patterns of entorhinal functional connectivity in aging |
| Q55003313 | Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology. |
| Q58120970 | Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease |
| Q64058197 | Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease |
| Q38803637 | Defining imaging biomarker cut points for brain aging and Alzheimer's disease |
| Q58552911 | Dendritic spine remodeling accompanies Alzheimer's disease pathology and genetic susceptibility in cognitively normal aging |
| Q47619556 | Dendritic spines provide cognitive resilience against Alzheimer's disease |
| Q58706105 | Detection of Alzheimer's Disease |
| Q47824973 | Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies. |
| Q57493164 | Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders |
| Q92265910 | Dissociable age and memory relationships with hippocampal subfield volumes in vivo:Data from the Irish Longitudinal Study on Ageing (TILDA) |
| Q90725338 | Dissociation of Tau Deposits and Brain Atrophy in Early Alzheimer's Disease: A Combined Positron Emission Tomography/Magnetic Resonance Imaging Study |
| Q38383420 | Distinct white matter injury associated with medial temporal lobe atrophy in Alzheimer's versus semantic dementia |
| Q92521608 | Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein |
| Q92402592 | Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span |
| Q91274849 | Effective connectivity in the default mode network is distinctively disrupted in Alzheimer's disease-A simultaneous resting-state FDG-PET/fMRI study |
| Q64998560 | Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. |
| Q46766203 | Elevated 18F-AV-1451 PET tracer uptake detected in incidental imaging findings |
| Q55311648 | Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. |
| Q46075858 | Entorhinal tau pathology, episodic memory decline and neurodegeneration in aging. |
| Q64051857 | Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer's disease pathology and cognitive symptoms |
| Q99412193 | Error propagation analysis of seven partial volume correction algorithms for [18F]THK-5351 brain PET imaging |
| Q64965222 | Evaluation of 18F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. |
| Q42330310 | Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy |
| Q104463890 | Evaluation of a visual interpretation method for tau-PET with 18F-flortaucipir |
| Q41654319 | Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum |
| Q47353532 | Extracellular Vesicle Biology in Alzheimer's Disease and Related Tauopathy |
| Q39447040 | Extracellular Vesicles Containing P301L Mutant Tau Accelerate Pathological Tau Phosphorylation and Oligomer Formation but Do Not Seed Mature Neurofibrillary Tangles in ALZ17 Mice |
| Q64115558 | F-Flortaucipir in TDP-43 associated frontotemporal dementia |
| Q61804682 | F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
| Q47684719 | Flortaucipir tau PET imaging in semantic variant primary progressive aphasia |
| Q48284478 | Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline |
| Q87865855 | Following the pathway to Alzheimer's disease |
| Q38663636 | Four Decades of Research in Alzheimer's Disease (1975-2014): A Bibliometric and Scientometric Analysis |
| Q92740033 | Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease |
| Q91635608 | Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease |
| Q31162702 | Future Directions in Imaging Neurodegeneration |
| Q90228188 | Genetic characterization of amyloid-β and tau network spread |
| Q90059833 | Genomic deletion of TLR2 induces aggravated white matter damage and deteriorated neurobehavioral functions in mouse models of Alzheimer's disease |
| Q45303896 | Gray matter asymmetries in aging and neurodegeneration: A review and meta-analysis |
| Q90707233 | Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948 |
| Q30100986 | Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex |
| Q90196747 | Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults |
| Q91961758 | Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships |
| Q37377931 | Hippocampal phospho-tau/MAPT neuropathology in the fornix in Alzheimer disease: an immunohistochemical autopsy study |
| Q60950130 | Imaging and Molecular Mechanisms of Alzheimer's Disease: A Review |
| Q49957645 | Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. |
| Q39419877 | Imaging tau pathology in Parkinsonisms |
| Q91692580 | Imaging the aged brain: pertinence and methods |
| Q91860896 | Imaging the evolution and pathophysiology of Alzheimer disease |
| Q37096041 | In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain |
| Q48687926 | In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. |
| Q64228804 | In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier |
| Q90697133 | Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease |
| Q91959371 | Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer's disease differ according to disease severity and amyloid positivity |
| Q89688294 | Is tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity |
| Q50422287 | Joint associations of β-amyloidosis and cortical thickness with cognition. |
| Q36970036 | Labeling Pathological Tau: An Important Quest for the Unknown |
| Q55254017 | Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias. |
| Q92920915 | Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease |
| Q46682283 | Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease |
| Q50026423 | Locus coeruleus integrity in old age is selectively related to memories linked with salient negative events. |
| Q51758098 | Longitudinal accrual of neocortical amyloid burden is associated with microstructural changes of the fornix in cognitively normal adults. |
| Q50531762 | Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake. |
| Q50583370 | Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia. |
| Q51763159 | Longitudinal tau PET in ageing and Alzheimer's disease. |
| Q50061690 | MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([(18)F]-AV-1451) Binding. |
| Q92649166 | MRI-Driven PET Image Optimization for Neurological Applications |
| Q26744646 | Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease |
| Q50531249 | Metabolic brain networks in aging and preclinical Alzheimer's disease. |
| Q97521007 | Mini Review: Opposing Pathologies in Cancer and Alzheimer's Disease: Does the PI3K/Akt Pathway Provide Clues? |
| Q47308968 | Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development |
| Q89918248 | Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease |
| Q54946040 | Molecular biomarkers of Alzheimer's disease: progress and prospects. |
| Q95841093 | Mosaic Somatic Gene Recombination as a Potentially Unifying Hypothesis for Alzheimer's Disease |
| Q39346750 | Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias |
| Q52589491 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. |
| Q47190278 | Networks of tau distribution in Alzheimer's disease |
| Q55407312 | Neural correlates of episodic memory in the Memento cohort. |
| Q90095665 | Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention |
| Q33907524 | Neurodegenerative disease: MRI biomarkers - a precision medicine tool in neurology? |
| Q90418013 | Neurofilament relates to white matter microstructure in older adults |
| Q58105827 | Neurogenetic contributions to amyloid beta and tau spreading in the human cortex |
| Q92591097 | Neuroimaging Biomarkers for Alzheimer's Disease |
| Q38646263 | Neuroimaging in aging: brain maintenance |
| Q87906376 | Neuronal Cell Death |
| Q64910410 | Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer's Disease. |
| Q90244120 | Neurophysiological signatures in Alzheimer's disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline |
| Q46566966 | PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). |
| Q38628805 | PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers |
| Q100490934 | PET amyloid in normal aging: direct comparison of visual and automatic processing methods |
| Q89642986 | PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan |
| Q51766173 | PET imaging of tau protein targets: a methodology perspective. |
| Q59544083 | PET staging of amyloidosis using striatum |
| Q90658867 | Parametric methods for [18F]flortaucipir PET |
| Q64062247 | Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau |
| Q48389127 | Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies |
| Q50054598 | Perspectives on How Human Simultaneous Multi-Modal Imaging Adds Directionality to Spread Models of Alzheimer's Disease. |
| Q38896981 | Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals |
| Q52969704 | Picture imperfect: Going beyond imaging amyloid in Alzheimer's disease. |
| Q47279644 | Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy |
| Q64255065 | Positron emission tomography of tau in Iraq and Afghanistan Veterans with blast neurotrauma |
| Q92970068 | Precision Aging: Applying Precision Medicine to the Field of Cognitive Aging |
| Q64890013 | Preserved Structural Network Organization Mediates Pathology Spread in Alzheimer's Disease Spectrum Despite Loss of White Matter Tract Integrity. |
| Q91882184 | Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework |
| Q46311193 | Probing the correlation of neuronal loss, neurofibrillary tangles, and cell death markers across the Alzheimer's disease Braak stages: a quantitative study in humans |
| Q92707326 | Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study |
| Q90591155 | Protein transmission in neurodegenerative disease |
| Q40259674 | Quantification of Tau Load Using [(18)F]AV1451 PET. |
| Q39002052 | Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer's disease. |
| Q64993260 | Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients. |
| Q57800439 | Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease |
| Q92972077 | Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy |
| Q39303669 | Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? |
| Q36311817 | Raman Spectrometric Detection Methods for Early and Non-Invasive Diagnosis of Alzheimer's Disease |
| Q52670912 | Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC. |
| Q49310065 | Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease. |
| Q47607239 | Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden |
| Q60301491 | Regional tau pathology and loneliness in cognitively normal older adults |
| Q90732288 | Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake |
| Q62830982 | Relationships Between Tau and Glucose Metabolism Reflect Alzheimer’s Disease Pathology in Cognitively Normal Older Adults |
| Q37739881 | Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition |
| Q91577860 | Scan-Time Corrections for 80-100-min Standardizetd Uptake Volume Ratios to Measure the 18F-AV-1451 Tracer for Tau Imaging |
| Q58092575 | Secondary prevention of Alzheimer's dementia: neuroimaging contributions |
| Q40277605 | Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study |
| Q92825260 | Sleep as a Potential Biomarker of Tau and β-Amyloid Burden in the Human Brain |
| Q38871392 | Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? |
| Q47926474 | Small-molecule PET Tracers for Imaging Proteinopathies |
| Q62830996 | Spatially Adaptive Varying Correlation Analysis for Multimodal Neuroimaging Data |
| Q95840152 | Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease |
| Q47869824 | Spread of tau deposits: can we trust in vivo findings? |
| Q55431921 | Staging of amyloid β, t-tau, regional atrophy rates, and cognitive change in a nondemented cohort: Results of serial mediation analyses. |
| Q49165313 | Static and Dynamic Cognitive Reserve Proxy Measures: Interactions with Alzheimer's Disease Neuropathology and Cognition. |
| Q48102802 | Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals |
| Q46683905 | Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly |
| Q62830975 | Subthreshold Amyloid Predicts Tau Deposition in Aging |
| Q53398002 | Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. |
| Q64054848 | Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models |
| Q62492915 | Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity |
| Q39016306 | Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials |
| Q90402876 | Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome |
| Q48027609 | Tau PET and tauopathies |
| Q91011085 | Tau PET imaging in neurodegenerative tauopathies-still a challenge |
| Q47985518 | Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. |
| Q34680852 | Tau PET imaging: present and future directions |
| Q46634925 | Tau PET: the next frontier in molecular imaging of dementia |
| Q37731919 | Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks |
| Q64903876 | Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer's Disease. |
| Q39365272 | Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases |
| Q90610537 | Tau Positron Emission Tomography Binding Is Not Elevated in HIV-Infected Individuals |
| Q94393283 | Tau and Pet/Mri Imaging Biomarkers for Detecting and Diagnosing Early Dementia |
| Q48234728 | Tau and amyloid β proteins distinctively associate to functional network changes in the aging brain |
| Q92221490 | Tau and atrophy: domain-specific relationships with cognition |
| Q41700392 | Tau and β-Amyloid Are Associated with Medial Temporal Lobe Structure, Function, and Memory Encoding in Normal Aging. |
| Q47886903 | Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. |
| Q64071535 | Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain |
| Q90950184 | Tau deposition is associated with functional isolation of the hippocampus in aging |
| Q64982207 | Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo. |
| Q46008245 | Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. |
| Q90089071 | Tau pathology in cognitively normal older adults |
| Q55416644 | Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. |
| Q47987344 | Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum |
| Q38990773 | Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition |
| Q47689697 | Tau-based therapies in neurodegeneration: opportunities and challenges |
| Q38633337 | Tau-imaging in neurodegeneration |
| Q93018917 | The "rights" of precision drug development for Alzheimer's disease |
| Q31147579 | The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement |
| Q61799060 | The Amazon rain forest plant Uncaria tomentosa (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles |
| Q46251905 | The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases |
| Q64109964 | The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory |
| Q88784001 | The Influence of Dopamine on Cognitive Flexibility Is Mediated by Functional Connectivity in Young but Not Older Adults |
| Q92187844 | The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE ε4 Non-carriers |
| Q52589490 | The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. |
| Q55437462 | The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer's Disease. |
| Q49322919 | The association between tau PET and retrospective cortical thinning in clinically normal elderly. |
| Q90006715 | The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes |
| Q56594907 | The development and validation of tau PET tracers: current status and future directions |
| Q42701971 | The emerging role of PET imaging in dementia. |
| Q90484535 | The impact of amyloid-beta and tau on prospective cognitive decline in older individuals |
| Q39004340 | The road to restoring neural circuits for the treatment of Alzheimer's disease |
| Q58725042 | The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease |
| Q33695122 | Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease |
| Q55463444 | Topographic staging of tau positron emission tomography images. |
| Q93087930 | Topographical Heterogeneity of Alzheimer's Disease Based on MR Imaging, Tau PET, and Amyloid PET |
| Q38382307 | Typical and atypical appearance of early-onset Alzheimer's disease: A clinical, neuroimaging and neuropathological study |
| Q50193680 | Uptake of AV-1451 in meningiomas. |
| Q36871202 | What amyloid ligands can tell us about molecular polymorphism and disease |
| Q93000468 | White matter alterations in early-stage Alzheimer's disease: A tract-specific study |
| Q37707241 | Whole Genome Expression Analysis in a Mouse Model of Tauopathy Identifies MECP2 as a Possible Regulator of Tau Pathology. |
| Q47330246 | Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia |
| Q57192742 | Widespread distribution of tauopathy in preclinical Alzheimer's disease |
| Q53397590 | [11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. |
| Q41350096 | [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy |
| Q90173686 | [18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window |
| Q47547648 | [18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. |
| Q47252490 | [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. |
| Q50103609 | [Biomarker-based diagnostics of Alzheimer's disease : Concept of suspected non-Alzheimer pathology]. |
| Q47694602 | [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging |
| Q42360584 | [F-18]AV-1451 positron emission tomography retention in choroid plexus: More than "off-target" binding |
| Q64261988 | rs242557 variant is associated with hippocampus tau uptake on F-AV-1451 PET in non-demented elders |
Search more.